Exact Sciences Stock News

Equities analysts predict that Exact Sciences Co. (NASDAQ:EXAS) will report earnings of ($0.87) per share for the current quarter, according to Zacks. Seven analysts have issued estimates for Exact Sciences earnings, with the highest EPS estimate coming in at ($0.42) and the lowest estimate coming in at ($1.17). Exact Sciences reported earnings per share of []

Exact Sciences Co. (NASDAQ:EXAS) has received a consensus recommendation of Buy from the fifteen ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month price []

Shares of Exact Sciences Co. (NASDAQ:EXAS) have been assigned an average rating of Buy from the fifteen research firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have assigned a buy rating to the company. []

Cathie Wood''s ETF Is Unraveling Cathie Wood''s ARKK is sinking. Her flagship ETF, the ARK Innovation Fund, which was already having a dismal year, lagging major indices about 35%, is plunging to end the week today. Heading into the close, it''s down about 6.3% and was down well below $100. On Friday, the damage got worse. Among Wood''s woes were her holdings in Docusign, which by mid-day was down an astonishing 41%. Additionally, Wood "bought the dip" by purchasing 2.1 million shares of Ginko Bioworks on Thursday, Bloomberg reported. On Friday, the stock fell by as much as 16%, at one point marking a 28% loss in just 5 days, amounting to $5 billion in value lost. Bloomberg noted that ARKK hit some ugly technical indicators on Friday, as well. The stock''s RSI plunged to 20 and saw a "trading range breakdown" according to technical analysis prepared by William Maloney, the voice of the U.S. equity squawk for Bloomberg. ETF expert Eric Balchunas put the performance in perspective on Friday.

Marshall Wace LLP lowered its position in Exact Sciences Co. (NASDAQ:EXAS) by 93.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,736 shares of the medical research companys stock after selling 25,014 shares during the period. Marshall Wace LLPs holdings in Exact []

New investors are facing their first big growth stock sell-off. Here are strategies to help you navigate it.

Exchange Traded Concepts LLC lifted its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS) by 5.8% during the third quarter, HoldingsChannel.com reports. The fund owned 30,590 shares of the medical research companys stock after purchasing an additional 1,667 shares during the quarter. Exchange Traded Concepts LLCs holdings in Exact Sciences were worth $2,920,000 as of []

Annex Advisory Services LLC cut its stake in Exact Sciences Co. (NASDAQ:EXAS) by 25.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,149 shares of the medical research companys stock after selling 740 shares during the quarter. Annex Advisory Services LLCs holdings in Exact []

The end of a co-promotion deal with Pfizer could work out well for Exact Sciences.

Exact Sciences Corporation (NASDAQ: EXAS) says that Pfizer Inc (NYSE: PFE) will no longer join the Company from November 30 to promote its Cologuard colorectal cancer screening test to health care

DNB Asset Management AS grew its position in Exact Sciences Co. (NASDAQ:EXAS) by 39.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 132,333 shares of the medical research companys stock after acquiring an additional 37,578 shares during the quarter. DNB Asset Management AS owned []

Beech Hill Advisors Inc. grew its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS) by 8.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,126 shares of the medical research companys stock after buying an additional 2,905 shares during the quarter. []

CHICAGO TRUST Co NA increased its position in Exact Sciences Co. (NASDAQ:EXAS) by 276.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,400 shares of the medical research company’s stock after purchasing an additional 6,900 shares during the quarter. […]

Don''t Look Now, But Cathie Wood''s Ark Is Taking On Water Among the biggest losers over the last 48 hour tech stock volatility has beenwell, everything in Cathie Wood''s "flagship" ARKK portfolio. Ergo, Wood''s ARKK fund has continued its dismal year, looking as though it could be heading back toward double digits any day now. Key components of Cathie Wood''s ARKK fund, including Tesla, Zoom, Spotify and DraftKings, are all lower in trading on Tuesday. Tesla is down more than 5% and names like Spotify and DraftKings were also down more than 5% at their lows during the cash session. Astute observers online are also starting to point out what can only be described as a massively widening delta between ARKK and all major indexes - to the tune of a whopping 40%! How long can investors ignore numbers like these from their favorite "active manager" before funds begin a deluge out of the way of all things Cathie Wood? $ARKK -16% YTD $QQQ +26% YTD $SPY +25% YTD DR. LUCID (@DRLUCID520) November 23, 2021 In addition, Wood''s Ark Genomic Revolution ETF has also been suffering outflows in November as returns lag.